Principally, breast cancer treatment modalities are based on surgery, radiotherapy, hormone-therapy and chemotherapy [ 2]. Of these treatment modalities, chemotherapy agents are used to induce cytotoxic impacts in cancerous cells through various mechanisms such as DNA detriments and inhibition of cell division and growth. For instance, MTX as one of the chemotherapeutic agents is commonly used for the treatment of metastatic breast cancer, acute myeloid leukemia and non-Hodgkin's lymphoma. It hinders cell proliferation through inhibition of topoisomerase II and disruption of DNA repair/synthesis [3], intercalation of DNA [4], DNA damage and apoptosis via inhibition of the mitochondrial pathway [5]. Unfortunately, administration of MTX is associated with inevitable initiation of inadvertent side effects (e.g. weakness, hair loss, diarrhea, heart problems and immunosuppression), mainly because of the non-specific effects on the healthy cells/tissue [6,7]. Further, cancer cells may become resistant to MTX. To tackle such dilemmas, cancer cells must be targeted with smart drug delivery nanosystems (NSs) to deliver anticancer agents such as MTX specifically into the tumor microenvironment (TME) and hence malignant cells.Among various NSs (e.g., nanoliposomes, polymeric NPs, dendrimers and other organic/inorganic NPs) designed for targeted therapy of cancer [ 8], MNPs appear to be one of the most promising delivery agents because they are biocompatible and can be easily decorated with homing and therapy agents [9]. Besides, potent toxic agents conjugated onto MNPs can be localized at the target site using an external magnetic field [10]. Targeted MNPs were shown to accumulate highly within the target tumor cells through passive and active targeting mechanisms while use of an external magnetic field can intensify the accumulation of MNPs [11][12][13]. Of various oncomarkers exploited for targeted therapy of cancer, folate receptors (FRs) have highly been overexpressed in various solid tumors such as breast and ovarian cancers [14,15]. Hence, FA, a safe small molecule also known as vitamin M or B9, has been used as homing device to target the FRs-overexpressing malignant cells. Owing to its versatility and conjugation simplicity, the FA-conjugation have been used for engineering multimodal nanomedicines and theranostics [16][17][18][19]. Surface modification of MNPs with polyethylene glycol (PEG) was shown to enhance the biocompatibility and the duration of blood circulation and to reduce the antigenicity of MNPs [20,21]. For example, Zhang et al. coated MNPs with PEG-FA and reported increased internalization of the modified MNPs in BT20 cells with decreased uptake in macrophages [22]. We have previously engineered multimodal PEGylated MNPs armed with FA and conjugated with MTX [23], or loaded with tamoxifen (TMX) [ 24]. We have also capitalized on functionalized MNPs to enhance the delivery of plasmid DNA into Escherichia coli [25]. In the current study, we aimed to study the cytotoxicity mechanism(s) of the PEGylated ...